Phathom Pharma

$19.80 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Phathom Pharma

Phathom Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing treatments for gastrointestinal (GI) diseases. Its product candidate, vonoprazan, is an oral small molecule potassium competitive acid blocker (P-CAB). It is developing vonoprazan as an agent in the treatment of gastroesophageal reflux disease (GERD) and in combination with antibiotics for the treatment of Helicobacter pylori (H. pylori) infection. Vonoprazan accumulates in the secretory canaliculus where the proton pumps are present in their active state. Vonoprazan binds to proton pumps in both their inactive and active states and remains in the secretory canaliculus where it continues to inhibit acid secretion over an extended period.

Stock Analysis

last close $20.81
1-mo return -28.7%
3-mo return -35.5%
avg daily vol. 198.76T
52-week high 50.78
52-week low 19.51
market cap. $631M
forward pe -
annual div. -
roe -124.5%
ltg forecast -
dividend yield -
annual rev. $--
inst own. 82.7%
baraka

Subscribe now for daily local and international financial news

Subscribe